SCHEMBL6794430

SCHEMBL6794430

CCc1cc(CCC(=O)C2CCCC2)cc(Cl)c1OCOCCOC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARG P13631 1/20 0.35
CTNNB1 P35222 1/20 0.33
REN P00797 6/20 0.33
THRA P10827 1/20 0.32
THRB P10828 1/20 0.32
DRD2 P14416 4/20 0.32
DRD3 P35462 4/20 0.32
HTR1A P08908 1/20 0.32
DRD4 P21917 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
HTR2B P41595 1/20 0.32
CYP3A4 P08684 3/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
MITF O75030 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3986354 0.84 DRD2 (0.38) THRATHRBDRD2DRD3DRD4
SCHEMBL3986226 0.76 F2 (0.39) RARGCTNNB1MEN1KMT2ANPSR1
SCHEMBL3993919 0.74 RARG (0.31) RARG
SCHEMBL3985034 0.70 RARG (0.36) RARGCTNNB1MEN1KMT2ACYP1A2
SCHEMBL26740106 0.68 THRA (0.41) RENTHRATHRBCYP3A4KMT2A
SCHEMBL3987889 0.67 OPRD1 (0.50) MEN1KMT2ATAS1R3TAS1R1
SCHEMBL3987891 0.67 KMT2A (0.49) MEN1KMT2A
SCHEMBL1464757 0.67 HSD11B1 (0.38) THRATHRBMEN1KMT2ACYP2C19
SCHEMBL5880935 0.66 PYGL (0.49) CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL25310429 0.66 MAPT (0.40) RENTHRATHRBCYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224960-A1 Pharmaceutical compositions and methods for their use AGOURON PHARMACEUTICALS, INC. 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224960-A1 Pharmaceutical compositions and methods for their use CYP3A5, CYP3A7, CYP3A43 RARG 3032/4885CTNNB1 4070/4885REN 679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.